Shkair Layaly, Garanina Ekaterina Evgenevna, Martynova Ekaterina Vladimirovna, Kolesnikova Alena Igorevna, Arkhipova Svetlana Sergeevna, Titova Angelina Andreevna, Rizvanov Albert Anatolevich, Khaiboullina Svetlana Francevna
Open Lab "Gene and Cell Technologies", Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.
Pharmaceutics. 2022 Jan 1;14(1):93. doi: 10.3390/pharmaceutics14010093.
Hemorrhagic fever with renal syndrome (HFRS) is an emerging infectious disease that remains a global public health threat. The highest incidence rate is among zoonotic disease cases in Russia. Most cases of HFRS are reported in the Volga region of Russia, which commonly identifies the Puumala virus (PUUV) as a pathogen. HFRS management is especially challenging due to the lack of specific treatments and vaccines. This study aims to develop new approaches for HFRS prevention. Our goal is to test the efficacy of microvesicles (MVs) as PUUV nucleocapsid (N) and glycoproteins (Gn/Gc) delivery vehicles. Our findings show that MVs could deliver the PUUV N and Gn/Gc proteins in vitro. We have also demonstrated that MVs loaded with PUUV proteins could elicit a specific humoral and cellular immune response in vivo. These data suggest that an MV-based vaccine could control HFRS.
肾综合征出血热(HFRS)是一种新出现的传染病,仍然是全球公共卫生威胁。发病率最高的是人畜共患病病例,在俄罗斯。大多数HFRS病例报告在俄罗斯伏尔加地区,该地区通常将普马拉病毒(PUUV)确定为病原体。由于缺乏特异性治疗方法和疫苗,HFRS的管理尤其具有挑战性。本研究旨在开发预防HFRS的新方法。我们的目标是测试微泡(MVs)作为PUUV核衣壳(N)和糖蛋白(Gn/Gc)递送载体的功效。我们的研究结果表明,MVs可以在体外递送PUUV N和Gn/Gc蛋白。我们还证明,装载有PUUV蛋白的MVs可以在体内引发特异性体液免疫和细胞免疫反应。这些数据表明,基于MVs的疫苗可以控制HFRS。